PD-1/PD-L1 Inhibition Enhances Chemotherapy-Induced Neuropathic Pain by Suppressing Neuroimmune Antinociceptive Signaling.

MLA

Wanderley, Carlos Wagner S., et al. “PD-1/PD-L1 Inhibition Enhances Chemotherapy-Induced Neuropathic Pain by Suppressing Neuroimmune Antinociceptive Signaling.” Cancer Immunology Research, vol. 10, no. 11, Nov. 2022, pp. 1299–308. EBSCOhost, https://doi.org/10.1158/2326-6066.CIR-22-0003.

APA

Wanderley, C. W. S., Maganin, A. G. M., Adjafre, B., Mendes, A. S., Silva, C. E. A., Quadros, A. U., Luiz, J. P. M., Silva, C. M. S., Silva, N. R., Oliveira, F. F. B., Gomes, F. I. F., Restrepo, J. L. J., Speck-Hernandez, C. A., Turaça, F., Silva, G. V. L., Pigatto, G. R., Nakaya, H. I., Mota, J. M., Barroso-Sousa, R., … Cunha, F. Q. (2022). PD-1/PD-L1 Inhibition Enhances Chemotherapy-Induced Neuropathic Pain by Suppressing Neuroimmune Antinociceptive Signaling. Cancer Immunology Research, 10(11), 1299–1308. https://doi.org/10.1158/2326-6066.CIR-22-0003

Chicago

Wanderley, Carlos Wagner S, Alexandre G M Maganin, Beatriz Adjafre, Atlante S Mendes, Conceição Elidianne Anibal Silva, Andreza Urba Quadros, João Paulo Mesquita Luiz, et al. 2022. “PD-1/PD-L1 Inhibition Enhances Chemotherapy-Induced Neuropathic Pain by Suppressing Neuroimmune Antinociceptive Signaling.” Cancer Immunology Research 10 (11): 1299–1308. doi:10.1158/2326-6066.CIR-22-0003.